CV Therapeutics Inc., adding to a line of biotech companies seeking (and getting) funding through debt financings, agreed to sell $100 million aggregate principal amount of 2 percent senior subordinated convertible debentures. (BioWorld Today)
Restructuring companies are sometimes seen as foundering entities and a reduction in head count can be viewed as a red flag or a sign of trouble within. (BioWorld Today)
Restructuring companies are sometimes seen as foundering entities and a reduction in head count can be viewed as a red flag or a sign of trouble within. (BioWorld Today)
